Cargando…

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma

PVR/TIGIT and PD-L1/PD-1 axes play essential roles in tumor immune evasion and could be potential targets for combined immunotherapy. We aimed to evaluate the expression status of the above-mentioned immune markers in lung squamous cell carcinoma (LUSC), and investigate their survival impact and rel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Zhenlin, Peng, Yue, Xu, Jiachen, Chen, Ping, Zhao, Zhenshan, Cai, Qingyuan, Li, Lin, Tian, He, Bai, Guangyu, Liu, Lei, Gao, Shugeng, He, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352965/ https://www.ncbi.nlm.nih.gov/pubmed/35926369 http://dx.doi.org/10.1016/j.tranon.2022.101501

Ejemplares similares

PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer
por: Yang, Zhenlin, et al.
Publicado: (2021)

TIGIT/CD47 dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma
por: Peng, Yue, et al.
Publicado: (2022)

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
por: Zhou, Xiuman, et al.
Publicado: (2020)

Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT
por: Zhou, Xiaowen, et al.
Publicado: (2021)

Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT
por: Diong, SJ J., et al.
Publicado: (2023)

Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma
por: Lee, Jii Bum, et al.
Publicado: (2021)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
por: Mu, Songlin, et al.
Publicado: (2022)

Publisher Correction: Overexpression of PVR and PD‑L1 and its association with prognosis in surgically resected squamous cell lung carcinoma
por: Lee, Jii Bum, et al.
Publicado: (2021)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
por: Zhong, Zhenwei, et al.
Publicado: (2022)

The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2022)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy
por: Niebel, Dennis, et al.
Publicado: (2022)

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
por: Simon, Sylvain, et al.
Publicado: (2020)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
por: Zhao, Jingjing, et al.
Publicado: (2023)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma
por: Guo, Wei, et al.
Publicado: (2021)

PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours
por: Davern, Maria, et al.
Publicado: (2022)

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia
por: Zhu, Liuluan, et al.
Publicado: (2017)

Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy
por: Zhou, Xiuman, et al.
Publicado: (2021)

High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2022)

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019)

PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow
por: Xu, Ling, et al.
Publicado: (2021)

TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma
por: Raphael, Itay, et al.
Publicado: (2021)

Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer
por: Peng, Hui, et al.
Publicado: (2022)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Perturbed CD8(+) T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals
por: Tauriainen, Johanna, et al.
Publicado: (2017)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v61nn0nfsnsc4k5ls1hi0f8eae